Liu Y - Search Results

1

5,5-Diphenyl-2-thiohydantoin-N10 (DPTH-N10) suppresses proliferation of cultured colon cancer cell line COLO-205 by inhibiting DNA synthesis and activating apoptosis.

Lee TS, Chen LC, Liu Y, Wu J, Liang YC, Lee WS. Lee TS, et al. Among authors: liu y. Naunyn Schmiedebergs Arch Pharmacol. 2010 Jul;382(1):43-50. doi: 10.1007/s00210-010-0519-4. Epub 2010 May 7. Naunyn Schmiedebergs Arch Pharmacol. 2010. PMID: 20449574

2

Anti-proliferation effect of 5,5-diphenyl-2-thiohydantoin (DPTH) in human vascular endothelial cells.

Shih CR, Wu J, Liu Y, Liang YC, Lin SY, Sheu MT, Lee WS. Shih CR, et al. Among authors: liu y. Biochem Pharmacol. 2004 Jan 1;67(1):67-75. doi: 10.1016/j.bcp.2003.08.018. Biochem Pharmacol. 2004. PMID: 14667929

3

Structure and anti-proliferation function of 5,5-diphenyl-2-thiohydantoin (DPTH) derivatives in vascular endothelial cells.

Cheng CK, Wu J, Liu Y, Lee TS, Kang SJ, Sheu MT, Lee WS. Cheng CK, et al. Among authors: liu y. Vascul Pharmacol. 2008 Feb-Mar;48(2-3):138-42. doi: 10.1016/j.vph.2008.01.007. Epub 2008 Feb 7. Vascul Pharmacol. 2008. PMID: 18295547

4

Anti-angiogenic action of 5,5-diphenyl-2-thiohydantoin-N10 (DPTH-N10).

Liu Y, Wu J, Ho PY, Chen LC, Chen CT, Liang YC, Cheng CK, Lee WS. Liu Y, et al. Cancer Lett. 2008 Nov 28;271(2):294-305. doi: 10.1016/j.canlet.2008.06.016. Epub 2008 Jul 22. Cancer Lett. 2008. PMID: 18649995

5

Inhibition of ubiquitin proteasome function suppresses proliferation of pulmonary artery smooth muscle cells.

Li M, Dong X, Liu Y, Sun X, Li Z, He J. Li M, et al. Among authors: liu y. Naunyn Schmiedebergs Arch Pharmacol. 2011 Dec;384(6):517-23. doi: 10.1007/s00210-011-0678-y. Epub 2011 Aug 19. Naunyn Schmiedebergs Arch Pharmacol. 2011. PMID: 21850573

6

Statins inhibit pulmonary artery smooth muscle cell proliferation by upregulation of HO-1 and p21WAF1.

Li M, Liu Y, Shi H, Zhang Y, Wang G, Xu J, Lu J, Zhang D, Xie X, Han D, Wu Y, Li S. Li M, et al. Among authors: liu y. Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):961-8. doi: 10.1007/s00210-012-0768-5. Epub 2012 Jul 22. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22820842

7

Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.

Xia X, Liu Y, Liao Y, Guo Z, Huang C, Zhang F, Jiang L, Wang X, Liu J, Huang H. Xia X, et al. Among authors: liu j, liu y. Eur J Pharmacol. 2019 Aug 5;856:172409. doi: 10.1016/j.ejphar.2019.172409. Epub 2019 May 25. Eur J Pharmacol. 2019. PMID: 31132355

8

Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling.

Liu N, Guo Z, Xia X, Liao Y, Zhang F, Huang C, Liu Y, Deng X, Jiang L, Wang X, Liu J, Huang H. Liu N, et al. Among authors: liu j, liu y. Eur J Pharmacol. 2019 Mar 5;846:1-11. doi: 10.1016/j.ejphar.2019.01.004. Epub 2019 Jan 9. Eur J Pharmacol. 2019. PMID: 30639309

9

Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.

Xia X, Huang C, Liao Y, Liu Y, He J, Guo Z, Jiang L, Wang X, Liu J, Huang H. Xia X, et al. Among authors: liu j, liu y. J Exp Clin Cancer Res. 2019 May 24;38(1):220. doi: 10.1186/s13046-019-1227-7. J Exp Clin Cancer Res. 2019. PMID: 31126320 Free PMC article.

10

Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.

Liao Y, Guo Z, Xia X, Liu Y, Huang C, Jiang L, Wang X, Liu J, Huang H. Liao Y, et al. Among authors: liu j, liu y. J Exp Clin Cancer Res. 2019 Apr 11;38(1):157. doi: 10.1186/s13046-019-1165-4. J Exp Clin Cancer Res. 2019. PMID: 30975171 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208,930 results

Search Page

Filters